To capture that transformation in motion, the team did something many earlier studies failed to do. Rather than relying on the human cell lines that dominate the radioresistance literature, lines that are poorly suited to immunocompetent systems and therefore blind researchers to the immune dimension of treatment failure, the investigators generated radioresistant isogenic variants of murine lung adenocarcinoma cell lines. Because these variants are genetically matched to their radiation-sensitive parents, any differences that emerge after repeated irradiation can be attributed to adaptive changes rather than pre-existing genetic background. The team then interrogated these paired models using transcriptomics, three-dimensional co-culture systems, and syngeneic mouse models that retain fully functioning immune systems.

The results paint a picture of tumors that have reorganized themselves at multiple levels simultaneously. The radioresistant clones displayed stable adaptations to DNA damage, including enhanced clonogenic survival after irradiation and constitutive activation of DNA damage response pathways, with the ATR pathway, named for the ataxia telangiectasia and Rad3-related kinase, standing out as particularly active. ATR functions as a master regulator of the cellular response to replication stress and DNA damage, and its persistent activation appears to give cancer cells a cushion against the strand breaks that ionizing radiation inflicts. Critically, the clinical relevance of this observation was not left to speculation: analyzing data from non-small cell lung cancer patients, the researchers found that high ATR levels were significantly associated with immunosuppression, linking a tumor-intrinsic survival mechanism to a hostile immune environment in human disease.

The transcriptomic analysis uncovered a second layer of the adaptation. Radioresistant tumors showed altered DNA repair programs alongside a marked downregulation of type-I interferon signaling and innate immune pathways. This is a crucial detail because radiation therapy, in addition to directly damaging DNA, is supposed to function as an in situ vaccine. When tumor cells die from irradiation, they are expected to undergo immunogenic cell death, releasing damage-associated molecular patterns that activate the cGAS-STING sensing axis and other innate pathways, which in turn recruit and activate cytotoxic T cells capable of finishing off survivors. By dampening these pathways, radioresistant tumors essentially mute the alarm system that radiation depends on to alert the immune system, reducing immunogenic cell death and converting what should be an inflammatory dying process into a quiet one.

The consequences of that muting were visible throughout the tumor microenvironment. In syngeneic mice, radioresistant tumors recruited a distinctly immunosuppressive cellular cast: increased numbers of T regulatory cells, M2-like macrophages, and myeloid-derived suppressor cells, along with reduced recruitment of cytotoxic T lymphocytes. These cell types are well-known accomplices of tumor survival, suppressing antitumor immunity through a variety of inhibitory signals and metabolic depletion. The three-dimensional co-culture experiments added a functional confirmation: when immunosuppressive cells were present alongside cancer cells in the same culture, they protected the malignant cells from radiation-induced cytotoxicity. In other words, the immune cells that radioresistant tumors attract are not bystanders. They are active participants in treatment failure, forming a shield that absorbs or suppresses the immune attack that radiation is meant to provoke.

Perhaps the most striking evidence for the centrality of immune suppression came from a transplant experiment of sorts. When the same radioresistant tumors were grown in immunodeficient mice, animals lacking the adaptive and innate immune machinery that normally shields the tumor, they regained their sensitivity to radiotherapy. Stripped of their immunosuppressive entourage, the tumors that had been so resilient in immunocompetent hosts became vulnerable again. This single observation reframes the entire problem of radioresistance: a substantial portion of it is not written into the cancer cell’s genome at all, but is instead conferred by the ecosystem the tumor has cultivated around itself.

That reframing immediately suggested therapeutic possibilities, and the team pursued them with encouraging results. The first approach involved artificially kick-starting innate immunity using agonists of Toll-like receptors, specifically the combination of poly(I:C), which activates TLR3, and R848, which targets TLR7 and TLR8. When these agonists were delivered to radioresistant tumors, they restored antitumor responses and improved the efficacy of radiotherapy, in part through a mechanism centered on the chemokines CXCL9 and CXCL10. These chemokines act as beacons for immune cells, and their induction re-established the recruitment of cytotoxic immune cells into the tumor, effectively rebuilding the alarm system that the radioresistant clones had dismantled. The findings give the study its title and its conceptual core: CXCL9-driven immune rewiring can restore the conditions under which radiation therapy works as intended.

The second approach attacked the problem from inside the cancer cell. Using ceralasertib, a pharmacological inhibitor of ATR, the researchers sensitized radioresistant tumors to radiation, directly undermining the constitutive DNA damage response activation that had given the cells their survival cushion. Together with the innate immune agonists, this establishes a rationale for combined strategies that hit both halves of the radioresistance program at once: stripping away the tumor’s molecular repair capacity with ATR inhibition while simultaneously reigniting the immune recruitment signals that allow radiation to trigger a lasting antitumor response. Neither approach alone represents a complete solution, but the logic of the combination, grounded in the mechanistic findings rather than empirical trial and error, is what distinguishes this work from earlier attempts to sensitize tumors to radiation.

The broader implications reach beyond lung cancer. The study demonstrates that the way radioresistance research is conducted matters: models lacking intact immune systems systematically obscure the contribution of the microenvironment, and this team’s decision to build isogenic immunocompetent models paid off with insights that would have been invisible in conventional systems. For clinicians treating non-small cell lung cancer, the work suggests that markers such as ATR expression and chemokine signatures could eventually help identify patients at risk of locoregional relapse before it occurs, and that combining radiotherapy with TLR agonists or ATR inhibitors deserves serious clinical evaluation. For now, the findings rest on preclinical evidence, and the usual caveats about translation from mice to humans apply. But they offer something that has been in short supply in this field: a mechanistically coherent account of how tumors learn to shrug off radiation, and a map of the vulnerabilities created along the way. As radiotherapy continues to anchor the treatment of lung cancer worldwide, strategies that restore rather than replace its power may prove to be the key to preventing the relapses that have long defied the beam.

Subject of Research: Mechanisms of radioresistance in non-small cell lung cancer involving ATR signaling and immune microenvironment rewiring

Article Title: CXCL9-driven immune rewiring and tumor-intrinsic ATR signaling inhibition restore radiotherapy response in lung cancer

Article References: Leon, S., Otegui, N., Redrado, M., Marchena-Perea, E. M., Guruceaga, E., Castro, F., Montuenga, L. M., Oliveira, M. J., Aristu, J. J., Serrano, D., & Calvo, A. (2026). CXCL9-driven immune rewiring and tumor-intrinsic ATR signaling inhibition restore radiotherapy response in lung cancer. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03834-z

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03834-z

Keywords: radiotherapy, non-small cell lung cancer, radioresistance, ATR inhibitor, ceralasertib, CXCL9, tumor microenvironment, immunosuppression, TLR agonists, innate immunity, DNA damage response, cancer immunotherapy

The logic of the new study rests on a vulnerability embedded in the biology of cancer itself: the DNA damage checkpoint. When anticancer drugs inflict lesions on DNA, healthy cells respond by halting the cell cycle through checkpoint pathways, buying time for repair before replication resumes. Two major checkpoints govern this process. The G1 checkpoint depends on the ATM–p53–p21 axis, while the G2/M checkpoint is controlled by the ataxia telangiectasia and Rad3-related kinase, or ATR, acting through Chk1 and Cdc25. Because malignant cells frequently carry p53 mutations and cannot arrest in G1, they become unusually dependent on the ATR-driven G2/M checkpoint to survive genotoxic stress. Normal cells, by contrast, retain a functional ATM–p53–p21 pathway. This asymmetry creates a therapeutic window: blocking ATR should selectively cripple cancer cells while sparing healthy tissue.

AZD6738, developed as an oral ATR inhibitor, does exactly that. By suppressing ATR-dependent phosphorylation—most notably Chk1 phosphorylation at serine 345—it disables the G2/M checkpoint that resistant tumors rely upon. The drug has already attracted attention across oncology, with Phase II trials suggesting clinical activity in combination with the immunotherapy durvalumab in previously treated advanced gastric cancer, particularly in patients lacking ATM expression, and in non-small cell lung cancer. Emerging data also support combinations with the PARP inhibitor olaparib in triple-negative breast cancer, with durvalumab in melanoma, and with radiotherapy. But in colorectal cancer, preclinical work on ATR inhibition had remained sparse. The Nagoya team had previously shown that AZD6738 potentiates both 5-FU and trifluridine in treatment-naïve colorectal cancer cells. The critical open question was whether that synergy survives the acquisition of 5-FU resistance—the setting in which trifluridine is actually given to patients.

To answer it, the researchers built a rigorous experimental system using two genetically defined human colorectal cancer cell lines, HCT116 and DLD-1, alongside 5-FU–resistant derivatives established through more than 100 passages of stepwise drug escalation. Both resistant sublines, HCT116/5FUR and DLD-1/5FUR, exhibited roughly 100-fold higher IC50 values for 5-FU than their parental counterparts, confirming profound acquired resistance. All cell lines were authenticated by short tandem repeat profiling and confirmed free of mycoplasma contamination. The team then designed experiments around a deliberately conservative dosing strategy: AZD6738 was used at 0.5 micromolar, a concentration shown to have no effect on proliferation after 72 hours in any of the four cell lines, so that any enhancement of cell killing could be attributed to genuine potentiation rather than simple additive toxicity.

The in vitro results were striking. As expected, 5-FU and its combination with AZD6738 lost all effectiveness in the resistant sublines—the combination that worked in parental cells was completely abrogated by acquired resistance, echoing earlier findings with Chk1 inhibitors. Trifluridine, however, told a different story. Although trifluridine alone was modestly weakened in the resistant cells, adding noncytotoxic AZD6738 significantly reduced cell viability across a wide dose range, from 1 to 1000 micromolar. Combination index analysis confirmed true synergy, with values of 0.735 in HCT116/5FUR and 0.418 in DLD-1/5FUR, where values below 1 indicate synergistic interaction. In time-course assays, the combination suppressed proliferation significantly at 72 hours in both resistant lines—p = 6.0 × 10⁻⁵ for HCT116/5FUR and p = 4.0 × 10⁻⁷ for DLD-1/5FUR—and restored a level of growth inhibition comparable to what trifluridine achieved in the parental, drug-sensitive cells. DLD-1/5FUR, the most resistant line, saw its trifluridine IC50 collapse from 155 micromolar to just 3.5 micromolar in the presence of AZD6738.

The molecular fingerprints of the combination revealed its mechanism. Western blotting showed that trifluridine alone produced little induction of γH2AX, a marker of DNA double-strand break signaling, but cotreatment with AZD6738 triggered a marked surge. Cleaved caspase-3, the executioner enzyme of apoptosis, rose far more strongly with the combination than with trifluridine alone, indicating that stalled checkpoint signaling had collapsed into programmed cell death. Meanwhile, the trifluridine-induced phosphorylation of Chk1 at Ser345—the very signal AZD6738 is designed to block—was suppressed by the drug, confirming on-target activity. Flow cytometry added a cell-cycle dimension: trifluridine alone drove a pronounced G2/M arrest, effectively locking damaged cells in a state of suspended repair, while the combination relieved that arrest, pushing cells past the checkpoint and into catastrophic division with unrepaired DNA damage.

Crucially, the synergy translated into living tumors. In a mouse xenograft model bearing DLD-1/5FUR tumors, neither TAS-102 alone nor AZD6738 alone significantly shrank tumors compared with controls. But the combination significantly suppressed tumor growth over the two-week treatment period, and at necropsy only the combination group showed a significant reduction in tumor weight relative to all other groups, including TAS-102 monotherapy (p = 0.039). Immunohistochemistry on excised tumors corroborated the mechanism in vivo: 25.8 percent of tumor cell nuclei stained positive for γH2AX in the combination group, compared with only 4.1 percent in the TAS-102 group. Equally important, safety signals were reassuring. Body weight did not differ among groups, and organ weights and blood counts showed no exacerbation of the hematologic toxicity that TAS-102 alone can induce, suggesting the addition of AZD6738 did not compound harm in this preclinical model.

The pharmacological reasoning behind the finding illuminates why trifluridine, unlike 5-FU, retains its potency in resistant tumors. Both drugs inhibit thymidylate synthase, an enzyme essential for DNA synthesis, and both can be incorporated into DNA and RNA. However, overexpression of thymidylate synthase is a major driver of 5-FU resistance, neutralizing the TS-inhibitory arm of both drugs. Trifluridine’s distinguishing feature is its exceptionally high rate of direct incorporation into DNA during S phase in place of thymidine, and earlier work by Emura and colleagues demonstrated that trifluridine retains substantial cytotoxicity in 5-FU–resistant colorectal cancer cells precisely because its activity depends largely on DNA incorporation rather than TS inhibition. That massive misincorporation generates replication stress, which the ATR–Chk1 axis manages at the G2/M checkpoint—making trifluridine and ATR inhibition a mechanistically rational pairing even after 5-FU resistance has taken hold.

The authors are candid about the study’s limitations. Mechanistic conclusions rest solely on pharmacological ATR inhibition without genetic validation; normal colon epithelial cells were not evaluated, leaving the therapeutic window uncertain; and only a single concentration of AZD6738 was tested, so broader dose–response studies will be needed. The roles of p53 and ATM also remain unresolved, as synergy appeared in both p53 wild-type and p53-mutant models, and no direct experiments interrogated these determinants. Nevertheless, the clinical relevance of the setting is hard to overstate: trifluridine is administered as TAS-102, known commercially as Lonsurf, almost exclusively after failure of fluoropyrimidine-based first- and second-line regimens, meaning most patients receiving it already harbor 5-FU resistance. By providing proof of concept that pharmacological ATR inhibition can restore—and even rescue—the antitumor activity of trifluridine in that refractory context, the study lays the groundwork for mechanistic follow-up and, ultimately, translational trials of a ceralasertib–TAS-102 combination in patients whose options are running out.

Subject of Research: ATR inhibition with AZD6738 to enhance trifluridine efficacy in 5-FU–resistant colorectal cancer

Article Title: AZD6738 (Ceralasertib) Enhances Trifluridine's Antitumor Effect in 5‐FU–Resistant Colorectal Cancer Cells

Article References: Uehara, S., Suzuki, T., Kato, J., Asai, H., Kato, A., Harata, S., Ushigome, H., Yamakawa, Y., Hirokawa, T., Takahashi, H., Matsuo, Y., & Takiguchi, S. (2026). AZD6738 (Ceralasertib) Enhances Trifluridine's Antitumor Effect in 5‐ FU –Resistant Colorectal Cancer Cells. Cancer Reports, 9(9), Article e70668. https://doi.org/10.1002/cnr2.70668

Image Credits: AI Generated

DOI: 10.1002/cnr2.70668

Keywords: AZD6738, ceralasertib, trifluridine, TAS-102, colorectal cancer, 5-FU resistance, ATR inhibitor, DNA damage checkpoint, Chk1, G2/M checkpoint, drug resistance, preclinical study

The new study, published in the British Journal of Cancer, focuses on a kinase called ATR, short for ataxia telangiectasia and Rad3-related protein. ATR sits at the heart of the cellular response to replication stress, the potentially lethal situation in which the molecular machinery that copies DNA stalls or breaks down. When chemotherapy drugs such as mitomycin C damage DNA, dividing cells rely heavily on ATR signalling to pause the cell cycle, stabilise stalled replication forks and coordinate repair. Block ATR pharmacologically, and cells exposed to DNA-damaging agents lose their safety net: replication forks collapse, DNA double-strand breaks accumulate, and the cell is pushed toward catastrophe. This concept, often described as exploiting a vulnerability created by the tumour’s own dependence on DNA damage checkpoints, has already shown promise in clinical trials of ATR inhibitors such as berzosertib in combination with platinum chemotherapy for advanced solid tumours.

What makes the Utrecht study distinctive is its model system. Rather than relying on immortalised cancer cell lines grown in two dimensions, which often fail to capture the biology of real tumours, the team used patient-derived organoids, miniature three-dimensional tumour cultures grown from tissue of six patients with non-muscle invasive bladder cancer. Organoids preserve many of the genetic and molecular features of the original tumours, including the expression of urothelial carcinoma markers, making them a far more faithful testing ground for new drug combinations. The researchers confirmed that their organoid lines expressed characteristic bladder cancer markers, validating them as genuine representatives of the disease they were designed to model.

The experimental design cleverly mimicked clinical practice. In patients, mitomycin C is delivered directly into the bladder as an instillation that remains in contact with the tumour tissue for roughly one to two hours before being drained. The researchers therefore exposed the organoids to mitomycin C for just two hours, replicating the transient exposure that tumour cells experience in the bladder, and only afterwards did they add ATR inhibitors, which the cells encountered for a prolonged 72-hour period. Three clinically relevant ATR inhibitors were tested: berzosertib, ceralasertib and tuvusertib, all of which have entered clinical trials in various cancers. The team also examined combinations with gemcitabine and epirubicin, two further agents used in intravesical chemotherapy regimens, in one organoid line.

The results were striking. Organoids treated with mitomycin C alone, or with an ATR inhibitor alone, eventually recovered: when the researchers followed the cultures for six weeks after treatment, the surviving cells proliferated at rates similar to untreated controls, demonstrating that neither agent on its own could eliminate the tumour cell population. In sharp contrast, organoids that received the sequential combination of mitomycin C followed by an ATR inhibitor showed severely impaired viability, and crucially, this effect persisted throughout the six-week observation period. The combination did not merely slow the cancer cells down; it appeared to destroy their capacity to regrow, which is precisely the property needed for a therapy intended to prevent recurrence after tumour resection.

Delving into the mechanism, the researchers showed that berzosertib potently suppressed the ATR signalling that mitomycin C normally triggers. DNA damage induced by the chemotherapy was marked by phosphorylated H2AX, a well-established molecular beacon of DNA double-strand breaks, and blocking ATR prevented the checkpoint response that would normally allow cells to survive this damage. Consistent with catastrophic, irreparable DNA damage, the combination treatment drove the organoid cells into apoptosis, the controlled programme of cell death. Quantitative analysis of the drug interaction using synergy scoring frameworks confirmed that the effect was genuinely synergistic rather than merely additive, meaning the two drugs together killed far more cells than would be predicted from their individual activities.

The implications for patients are considerable. Recurrence after intravesical therapy remains the central clinical challenge in non-muscle invasive bladder cancer, driving repeated surgeries, lifelong surveillance and, in a substantial minority of cases, progression to life-threatening muscle-invasive disease. The economic burden of bladder cancer across Europe is among the highest of any malignancy, largely because of the intensity of monitoring and repeat treatment that recurrence entails. A regimen that converts transient chemotherapy exposure into durable eradication of residual tumour cells could reduce recurrence rates, spare patients repeated interventions and delay or prevent progression. Because ATR inhibitors such as berzosertib, ceralasertib and tuvusertib are already in clinical development, the path from laboratory finding to clinical testing is shorter than for an entirely novel drug class.

There are important caveats. The study is preclinical, conducted in organoids rather than in patients, and although organoids are among the most clinically predictive laboratory models available, they cannot fully reproduce the immune system, the bladder wall architecture or the complex urine environment that shapes drug activity in vivo. The number of organoid lines tested, six for the mitomycin C combinations, is modest, and the gemcitabine and epirubicin experiments were limited to a single line, so the generality of the synergy across the molecular diversity of bladder cancer remains to be established. Questions also remain about the optimal sequencing, dosing and delivery of ATR inhibitors in the bladder, and about whether systemic administration would be needed or whether the inhibitors could themselves be delivered intravesically to limit side effects.

Nevertheless, the study provides a compelling proof of principle that the DNA damage response is a druggable Achilles heel of non-muscle invasive bladder cancer, and it establishes patient-derived organoids as a practical platform for optimising intravesical combination therapies before they are tested in the clinic. The findings build on a growing body of evidence that ATR inhibition sensitises bladder tumours to DNA-targeted agents, including earlier work showing enhanced cisplatin and gemcitabine activity in bladder cancer cell lines and clinical trial data combining berzosertib with platinum chemotherapy in advanced urothelial carcinoma. If the synergy observed in these miniature tumours translates to patients, the humble bladder instillation, a treatment whose basic design has changed little in decades, could be transformed into a precision strike that leaves behind not just damaged cancer cells, but none at all.

Subject of Research: Combining ATR kinase inhibitors with intravesical chemotherapy to prevent recurrence in non-muscle invasive bladder cancer, tested in patient-derived organoids.

Article Title: ATR inhibitors synergise with mitomycin C to enhance cytotoxicity in patient-derived non-muscle invasive bladder cancer organoids

Article References: Zuidema, A., Nijland, L., van Megesen, K., Vosjan, M. M., Viergever, B. J., Kranenburg, O., & Meijer, R. P. (2026). ATR inhibitors synergise with mitomycin C to enhance cytotoxicity in patient-derived non-muscle invasive bladder cancer organoids. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03581-0

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03581-0

Keywords: bladder cancer, ATR inhibitors, mitomycin C, patient-derived organoids, DNA damage response, non-muscle invasive bladder cancer, berzosertib, ceralasertib, tuvusertib, intravesical chemotherapy, drug synergy, cancer recurrence